2752-38-7

Basic information

• Product Name: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid
• Synonyms: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid
• CAS NO: 2752-38-7
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.27
• Mol File: 2752-38-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 469.5°C at 760 mmHg
• Flash Point: 237.7°C
• Appearance: /
• Density: 1.267g/cm³
• Vapor Pressure: 1.28E-09mmHg at 25°C
• Refractive Index: 1.586
• CAS DataBase Reference: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid(2752-38-7)
• EPA Substance Registry System: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid(2752-38-7)

Safety Data

• Hazardous Substances Data: 2752-38-7(Hazardous Substances Data)

Usage

Description

(S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid, commonly known as Modafinil, is a pharmaceutical compound with a primary function in the treatment of sleep disorders such as narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea. It is recognized for its ability to stimulate the central nervous system, particularly by increasing dopamine release in the brain, which leads to enhanced arousal, alertness, cognitive function, and memory. Modafinil is considered to have a low potential for abuse and addiction, and is generally safe when used as prescribed, although it may cause side effects and should be used cautiously in individuals with certain health conditions.

Uses

Used in Pharmaceutical Industry:
Modafinil is used as a therapeutic agent for the treatment of sleep disorders, specifically narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea. It is valued for its ability to increase dopamine release in the brain, which results in improved alertness and cognitive function.
Used in Cognitive Enhancement:
Modafinil is used off-label as a cognitive enhancer, aiming to improve wakefulness and cognitive performance in individuals with fatigue-related conditions. Its mechanism of action, which includes the stimulation of the central nervous system, makes it a candidate for enhancing cognitive abilities in certain populations.
Used in Research and Development:
In the context of research and development, Modafinil is utilized to study the effects of dopamine release on the central nervous system and to explore its potential applications in various cognitive and neurological conditions. This includes investigating its safety, efficacy, and optimal dosages for different uses.

InChI:InChI=1/C13H15NO3/c15-12(9-10-5-2-1-3-6-10)14-8-4-7-11(14)13(16)17/h1-3,5-6,11H,4,7-9H2,(H,16,17)/t11-/m0/s1

Upstream product

• 103-80-0 phenylacetyl chloride 
• 147-85-3 L-proline 
• 609-36-9 rac-Pro-OH 
• 78348-56-8 (2S)-1-(phenylacetyl)pyrrolidine-2-carboxylic acid methyl ester 
• 16652-71-4 benzyl (2S)-2-pyrrolidinecarboxylate hydrochloride 
• 103-82-2 phenylacetic acid 
• 88105-65-1 (S)-1-phenylacetyl-pyrrolidine-2-carboxylic acid benzyl ester 
• 147-85-3 L-proline 

Downstream Products

• 282534-27-4 1-[1-(phenylacetyl)-2-pyrrolidinyl]acetone 
• 1312611-08-7 C₁₉H₂₁BN₂O₄ 
• 1312611-09-8 C₃₄H₃₅N₃O₄ 
• 1312611-10-1 C₂₉H₂₇N₃O₂ 
• 1312609-13-4 C₄₂H₄₀N₄O₄ 
• 1312609-05-4 C₃₉H₃₉N₅O₅ 
• 1312611-00-9 C₂₆H₂₄N₄O₅ 
• 1312611-01-0 C₂₆H₂₆N₄O₃ 
• 1219630-12-2 (2S,2’S)-N,N’-(1,2-ethynediyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide) 
• 1313744-14-7 (2S,2'S)-N,N'-(4,4'-(1H-pyrazole-3,5-diyl)bis(4,1-phenylene))bis(1-(2-phenylacetyl)pyrrolidine-2-carboxamide) 
• 1313744-67-0 (2S,2'S)-N,N'-(4,4'-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-(2-phenylacetyl)pyrrolidine-2-carboxamide) 
• 78348-56-8 methyl ester of N-phenylacetyl-L-proline 
• 157115-89-4 N-phenylacetyl-L-prolyl-L-asparginic acid diethyl ester 

Relevant articles and documents

N-phenylacetyl-L-proline preparation method

The invention discloses an N-phenylacetyl-L-proline preparation method which includes the steps: dripping phenyl acetyl chloride and acid-binding agents into an organic solvent dissolved L-proline atlow temperature; adding a phase transfer catalyst, perfo

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Synthesis and antiamnesic activity of a series of N-acylprolyl-containing dipeptides

Eaters and amides of a series of N-acylprolyl-containing dipeptides were synthesized. It was established that these substances possess the ability to prevent memory decline evoked by maximal electroshock (MES) in a passive avoidance step-through paradigm. These N-acylprolyl-containing dipeptides were designed as analogues of pyroglutamyl-containing dipeptides, which we previously demonstrated to be highly active nootropics. Among the structure-activity relationships explored were the effect of N-acylsubstitution size, C-terminal substitution and the nature of the second amino acid. The optimal N-acyl moiety was the N-phenyl-acetyl group, while the optimal C-terminal substitution-esters were those derived from low alkyl alcohols. The optimal second amino acids were Asp, Glu or their fragments, Gly, β-Ala, GABA. Compound 1 (N-phenylacetylprolylglycine ethyl eater) was selected for further evalution in impaired cognitive functions. It was supposed that esters and unsubstituted amides of N-acylprolylglycines are prodrugs, which convert to the bioactive cyclo-(Pro-Gly) by virtue of enzymatic or chemical lability within the body.